Japan Pulmonary Arterial Hypertension Market Size & Outlook
Japan pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Japan pulmonary arterial hypertension market highlights
- The Japan pulmonary arterial hypertension market generated a revenue of USD 246.6 million in 2023 and is expected to reach USD 369.4 million by 2030.
- The Japan market is expected to grow at a CAGR of 5.9% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- PDE-5 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 246.6 million |
| Market revenue in 2030 | USD 369.4 million |
| Growth rate | 5.9% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | PDE-5 Inhibitors |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Japan accounted for 3.3% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 191.4 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.36% in 2023. Horizon Databook has segmented the Japan pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Japan holds a considerable share of the Asian PAH market. It has a relatively high geriatric population. A shift toward western diet and lifestyle has increased the incidence of coronary diseases, leading to higher market demand.
With a high healthcare expenditure, Japan’s healthcare system is witnessing a transition, expanding the service portfolio from preventive care to nursing care in disease management. The “21st-century type social security scheme” is expected to open more avenues for the Japanese PAH market.
Thus, the Japanese market is anticipated to account for around 21.7% of the market share of the overall Asia Pacific PAH market in 2020. According to European Respiratory Journal, prevalence of PAH in the country was estimated to be around 15.6 per million in 2017. The gender ratio was 1:2.17 for males: females, reflecting predominance of women.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Japan Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
